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Obesity is a metabolic disorder developed by overnutrition and a major cause for insulin
resistance and cardiovascular events. Since adipose tissue is one of the major sites for
the synthesis and secretion of cytokines, enlarged adipose tissue in obese condition alters
inflammatory state leading to pathophysiological conditions such as type 2 diabetes and
increased cardiovascular risk. A plausible theory for development of metabolic dysregu-
lation is that obesity increases secretion of inflammatory cytokines from adipose tissue
and causes a chronic inflammation in the whole body. Additionally accumulation of lipids
in non-adipose tissues elevates the cellular levels of bioactive lipids that inhibit the sig-
naling pathways implicated in metabolic regulation together with activated inflammatory
response. Recent findings suggest that obesity-induced inflammatory response leads to
modulation of sphingolipid metabolism and these bioactive lipids may function as medi-
ators for increased risk of metabolic dysfunction. Importantly, elucidation of mechanism
regarding sphingolipid metabolism and inflammatory disease will provide crucial informa-
tion to development of new therapeutic strategies for the treatment of obesity-induced
pathological inflammation.
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INTRODUCTION
Obesity is an outcome of overnutrition, less exercise, and seden-
tary lifestyle. Outcomes of obesity include cardiovascular disease
(CVD), diabetes, and hyperlipidemia and contribute to increased
mortality and morbidity after myocardial infarction and related
complications in diabetic compared with non-diabetic patients
(Stone et al., 1989). Even with various current interventions, the
occurrence of obesity is increasing and medical expenses associ-
ated with curing obesity and its complications are increasing as
well (Finkelstein et al., 2009). Deposition of ectopic fat in adi-
pose tissue is associated with increased plasma fatty acids (FA)
which are the major contributor to increased lipid contents in
non-adipose tissues. Since the adipose tissue is the major place
for the pathogenesis of obesity-related metabolic and cardiovas-
cular dysfunction, it has drawn much attention as a target tissue.
Obesity worsens tissue functions and contributes to increased risk
of development of hypertensions, atherosclerosis, diabetes, and
non-alcoholic fatty liver disease (NAFLD) (Flegal et al., 2007). To
elucidate the mechanism of pathophysiology of obesity-associated
diseases, lipotoxicity and inflammation have been suggested as
major contributors to progression of chronic diseases associated
with obesity. Among various bioactive lipid metabolites, sphin-
golipids have been studied due to its implication in development
of various chronic metabolic diseases and its bioactive charac-
teristics to modulate cellular signaling pathways (Johns et al.,
1998; Shimabukuro et al., 1998; Pettus et al., 2002; Amati et al.,
2011). In addition, obesity elevates production of proinflamma-
tory cytokines, chemokines, and coagulation proteins and medi-
ates multiple processes in the body (Hotamisligil et al., 1993, 1995).
As a result, inflammation is associated with obese conditions and
infiltration of macrophages and T lymphocytes are usually accom-
panied (Hotamisligil et al., 1993, 1995; Ferrante, 2007). Recent
reports demonstrated that sphingolipid metabolism is modulated
in obese conditions that alter inflammatory state in adipose tissues
and immune cells (Kolak et al., 2007; Holland et al., 2011a). In this
review, we will focus on sphingolipid metabolism in the etiology
of chronic diseases accompanied with obesity-mediated inflam-
mation. Understanding the role of sphingolipids will provide
effective therapeutic targets for obesity-mediated inflammation
(Hotamisligil et al., 1993).
ADIPOSE TISSUE INFLAMMATION
The adipose tissues has been considered as a lipid storing organ
accumulating triglycerides (TAG) in adipocytes in response to
overnutrition and releasing these stored lipids during fasting.
However, the notion that adipose tissue produces and releases var-
ious cytokines, termed “adipokines,” represents this is an active
inflammatory organ. The fact that adipose tissue is an active
inflammatory organ was initiated from the findings that adipose
tissue has increased expression of tumor necrosis factor-α (TNFα)
in obese human compared with lean individuals (Hotamisligil
et al., 1995). Since this report, it has been reported that adipose
tissue from the obese individuals has increased expression and
secretion of several proinflammatory cytokines such as tumor
necrosis factor-α (TNFα), monocyte chemoattractant protein-1
(MCP-1), interleukin-6 (IL-6), iNOS, C-reactive protein (CRP),
and plasminogen activator inhibitor type-1 (PAI-1) (Figure 1)
(Mohamed-Ali et al., 1997; Fried et al., 1998; Visser et al., 1999;
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FIGURE 1 | Enlarged adipocytes by obesity contribute to systemic
inflammation and lipotoxicity due to increased cytokines and
accumulation of lipid metabolites in non-adipocyte tissues. DAG,
diacylglycerol; TAG, triacylglycerol; Cer, ceramide; Sph, sphingosine.
Perreault and Marette, 2001; Christiansen et al., 2005). Hyper-
trophied adipocytes induce infiltration of activated macrophages
which mediates increased expression and secretion of a variety
of proinflammatory cytokines in systemic circulation (Weisberg
et al., 2003).
Various adipokines have been suggested as useful biomark-
ers for CVD and metabolic dysregulation associated with obe-
sity. Depending on the fat contents in the body, the species and
the amounts of adipokines secreted from adipose vary. Expres-
sion of anti-inflammatory cytokines is upregulated including
adiponectin, leptin and IL-10 in response to decreased fat mass
(Yang et al., 2001). These adipokines have beneficial effects by
regulating body weight due to reduced food intake/energy expen-
diture and reducing inflammation (Friedman and Leibel, 1992;
Zhang et al., 1994; Friedman and Halaas, 1998; Kadowaki et al.,
2006). In contrast, expression of proinflammatory cytokines (such
as TNFα, MCP-1, and IL-1β) is upregulated with fat mass increase
in adipocytes (Jung et al., 2008). Elevation of these cytokines in
circulation promotes insulin resistance in peripheral tissues by
inhibition of signaling intermediates (Hotamisligil et al., 1995).
Another outcome of obesity is increased lipid accumulation in
non-adipose tissues (Kraegen et al., 2001; Unger, 2003). Saturated
fat storage capacity of adipose tissue spills free fatty acids (FFAs)
in circulation with lipolysis and leads to accumulation of ectopic
fat in the tissues not suited for fat storage (Figure 1). Increased
FFAs and cytokines activate immune receptors and stress signal-
ing pathways that interfere with insulin signaling in muscle and
liver (Holland et al., 2007, 2011a; Hoehn et al., 2008). As non-
oxidative pathway of FFAs, intracellular and circulating ceramide
are elevated and bioactive sphingolipids such as ceramide, sphin-
gosine, and sphingosine 1-phosphate (S1P) are now known to link
overnutrition, inflammation, and metabolic dysregulation.
SPHINGOLIPID METABOLISM IN OBESITY-INDUCED
INFLAMMATION
Sphingolipid metabolism is highly regulated by a complex net-
work of interconnected pathways not simply by availability of
substrate FFAs. Major bioactive sphingolipids includes ceramide,
sphingosine, S1P, and ceramide-1-phosphate (C1P) act as signal-
ing molecules regulating various physiological events such as cell
proliferation, apoptosis, and inflammation (Futerman and Han-
nun, 2004; Hannun and Obeid, 2008; Morad and Cabot, 2013).
Ceramide is a major molecule in sphingolipid metabolism and a
precursor of complex sphingolipids.
De novo biosynthesis of ceramide is initiated from condensa-
tion of serine and palmitoyl CoA by serine palmitoyltransferase
(SPT) followed by a series of reactions involving the enzymes
3-ketosphinganine reductase, ceramide synthase (CerS), dihydro-
ceramide desaturase (DES). Another pathway to produce ceramide
is through hydrolysis of sphingomyelin (SM) by acid or neutral
sphingomyelinase (SMase) (Hannun and Obeid, 2008) (Figure 2).
Ceramide is further deacylated to generate sphingosine by alkaline
or acid ceramidase and sphingosine is phosphorylated to pro-
duce S1P by sphingosine kinases. Ceramide kinase phosphorylates
ceramide to produce C1P (Sugiura et al., 2002). The sphingolipid
biosynthesis pathway affects cellular production of at least four
known bioactive lipids: ceramide, sphingosine,S1P,and C1P. These
signaling lipids are known to alter various physiological events by
regulating signaling pathways.
Accumulating evidence suggest that ceramide synthesis can
be activated by increased availability of FFAs, proinflammatory
cytokines, oxidative stress, and hormones (Memon et al., 1998;
Samad et al., 2006; Schilling et al., 2013). All of these condi-
tions represent the obese conditions of adipose tissue and suggest
that ceramide metabolism may be altered in the obese. Indeed,
ceramide levels were elevated in skeletal muscle, liver, and hypo-
thalamus in obese rodents and human (Adams et al., 2004; Holland
et al., 2007; Reyna et al., 2008). Samad et al. (2006) demonstrated
that total SM and ceramide levels were reduced in the adipose tis-
sues from the leptin deficient ob/ob mice. In contrast, plasma
SM, ceramide, sphingosine, and S1P were elevated in plasma.
Since expression of ceramide synthetic genes including SPT, neu-
tral SMase, and acid SMase is upregulated in adipose tissue, this
opposite sphingolipid profiles in plasma and adipose tissue suggest
that secretion of ceramide from adipose tissues into circulation is
increased.
Obesity elevates TNFα expression in adipose tissues (Hotamis-
ligil and Spiegelman, 1994) and ceramide is elevated via hydrolysis
of SM by SMases and SPT-mediated de novo synthesis. The find-
ings that intraperitoneal administration of TNFα into C57BL/6J
mice upregulates acid SMase, neutral SMase, and SPT suggest
increased ceramide synthesis in adipose tissue (Samad et al., 2006).
To support this report, Holland et al. (2011a) demonstrated that
there is an overlap between inflammatory status and ceramide
production converging on the Toll-like receptor 4 (TLR4) path-
way independent of TNFα signaling. In mutant mice lacking
functional TLR4, increased ceramide production by saturated
FA or lipopolysaccharides (LPS) was prevented in skeletal mus-
cle and liver. Saturated fat induces ceramide production and
inflammatory response in a TLR4-dependent manner. Recently,
Schilling et al. (2013) reported that the combination of LPS
and palmitate synergistically activates ceramide production via
TLR4-dependent and independent signaling respectively. Thus,
correlation of ceramide metabolism and inflammatory state has
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FIGURE 2 | Sphingolipid biosynthetic pathways. Inhibition of indicated biosynthetic enzymes is associated with prevention of chronic metabolic diseases.
SPT, serine palmitoyltransferase; DES1, dihydroceramide desaturase 1; SMS, sphingomyelin synthase.
been established by involvement of TLR4 and cytokine-mediated
activation of SMase.
ADIPONECTIN, S1P, AND SPHINGOLIPID METABOLISM
Obesity increases systemic inflammation state together with pro-
duction and secretion of proinflammatory cytokines and reduces
production of anti-inflammatory cytokines. While TNFα activates
proinflammatory pathways and mediates apoptosis, adiponectin
inhibits proinflammatory cytokine-mediated pathways and pro-
motes cell proliferation (Ouchi et al., 2000; Kobayashi et al., 2004).
Adiponectin is an anti-inflammatory adipokine usually found
in circulation (Fang and Sweeney, 2006; Kadowaki et al., 2008).
Adiponectin forms three oligomeric forms that can be cleaved
by leukocyte elastase to liberate the globular C-terminal frag-
ment which exerts its biological activity (Waki et al., 2005; Wang
et al., 2006). Plasma adiponectin levels are generally reduced in
the individuals with increasing obesity and diabetes (Liu et al.,
2007). Pathophysiological events including diabetes, inflamma-
tion, and atherosclerosis are known to be alleviated by adiponectin
(Abel et al., 2008; Shetty et al., 2009). These beneficial effects
of adiponectin have been attributed to its insulin-sensitizing
and insulin-like effects in skeletal muscle and liver. Adiponectin
enhances glucose uptake and acts as a stimulator of FA uptake
and oxidation via AMP-dependent kinase pathway (AMPK) (Fang
and Sweeney, 2006; Kadowaki et al., 2008; Matsuzawa, 2010).
Alleviation of lipotoxicity by adiponectin contributes to reduced
metabolic dysregulation.
Recent findings by Holland et al. (2011b) demonstrated
the linkage between adiponectin and sphingolipid metabolism.
Adiponectin receptors contain an inherent ceramidase activity
and reduce ceramide. Activity of ceramidase activity is depen-
dent on amount of adiponectin levels and regulated by its biding
to the receptors. Adiponectin binding to its two receptors, Adi-
poR1 and AdipoR2, stimulates ceramidase activity and formation
of sphingosine from ceramide degradation is stimulated. Produced
sphingosine is phosphorylated by sphingosine kinase to produce
S1P, a major bioactive sphingolipid metabolite exerting its anti-
apoptotic and anti-diabetic effects. Formed S1P is transported
to extracellular environment, binds to the S1P receptors, elevates
intracellular calcium, and activates AMPK. Indeed, insulin toler-
ance is much improved in adiponectin transgenic mice fed a high
fat diet when compared to WT mice fed a high fat diet. In opposite
to the action of ceramide, S1P has been known to activate Akt
and promotes cell proliferation (Morales-Ruiz et al., 2001; Spiegel
and Milstien, 2003; Chavez et al., 2005). These findings suggest
that inflammatory cytokines are closely linked to modulation of
sphingolipid metabolism. S1P and ceramide has opposite roles
and regulate the fate of cells for survival or death,“rheostat theory
of sphingolipids” in body metabolism.
CERAMIDE AND HYPOTHALAMIC REGULATION OF FEEDING
Elevated FA in circulation is due to obesity-mediated spillover
from adipose tissue. Central nervous system regulates appetite and
energy homeostasis and hypothalamus controls food intake and
its metabolism (Schwartz et al., 2000). Recent reports clearly show
that FA in hypothalamus plays an important role in energy balance
(Obici et al., 2003; He et al., 2006; Lopez et al., 2006). Especially,
malonyl CoA, a precursor of de novo FA biosynthesis, draws atten-
tions as a regulator of hypothalamic control (Loftus et al., 2000;
Gao and Lane, 2003; Gao et al., 2007). Leptin, an adipokine regu-
lating food intake and body weight, elevates malonyl CoA levels in
hypothalamic arcuate nucleus (Arc) and partly causes its anorex-
igenic effects (Gao et al., 2007). Carnitine palmitoyltransferase-1
(CPT-1) activity, a key enzyme in mitochondrial FA β-oxidation,
is inhibited by malonyl CoA and exerts leptin-mediated anorexia
(Wolfgang et al., 2007). Wolfgang et al. (2006) have demonstrated
hypothalamic CPT-1c, a brain-specific CPT-1 isoform expressed
in hypothalamic Arc neuron, is implicated in energy homeostasis.
While CPT-1 liver isoform (CPT-1a and -1b) is a predominant
form possessing the acyltransferase activity (Obici et al., 2003),
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CPT-1c has a very weak enzyme activity. Importantly, CPT-1c
knockout (KO) animals have reduced food intake and weight
gain suggesting a critical role of CPT-1c in energy homeostasis
(Wolfgang et al., 2006).
Recently, Gao et al. (2011) have shown that adenoviral overex-
pression of CPT-1c in hypothalamic Arc increases food intake
and upregulates orexigenic neuropeptide Y (NPY) and Bsx, a
transcription factor of NPY. Interestingly, CPT-1c overexpression
elevated ceramide levels and CPT-1c KO resulted in the opposite,
a reduced ceramide levels (Gao et al., 2011). The intra-Arc infu-
sion of C6-ceramide, a cell-penetrating ceramide analog, resulted
in blockade of leptin- or cerulenin-mediated anorexigenic effects.
In contrast, inhibition of de novo ceramide synthesis by myriocin
resulted in reduced food intake and body weight. Since CPT-1c
and SPT are expressed in ER, palmitoyl CoA might be available
via CPT-1c action and supplied for de novo ceramide biosynthesis
in ER. Another possibility is that CPT-1c acts as a transporter of
palmitoyl CoA into ER. Taken together, FA metabolism by CPT-1c
exerts its anorexigenic regulation by modulating ceramide synthe-
sis. Although the exact mechanism of CPT-1c/ceramide pathway
and regulation of energy homeostasis regarding major Arc neu-
rotransmitters should be studied further, these findings suggested
the novel role of ceramide in CNS control of appetite and whole
body energy metabolism.
INVOLVEMENT OF SPHINGOLIPID METABOLISM IN
DEVELOPMENT OF CHRONIC DISEASES BY OBESITY
INSULIN RESISTANCE
Obesity is closely associated with an increased development of
insulin resistance. The concept that inflammation elicited by obese
conditions contributes to diabetes was initiated from the findings
that adipose-released proinflammatory cytokines inhibit insulin
signaling in the adipose, skeletal muscle, and liver (Hotamisligil
et al., 1993). Insulin regulates glucose homeostasis by activat-
ing glucose uptake by the skeletal muscle and adipose tissue and
inhibiting hepatic glucose output. In addition, insulin stimulates
FA uptake, TAG biosynthesis, and storage in adipose tissue. Insulin
resistance is a pathophysiological process associated with reduced
response of target tissues, hyperinsulinemia, and elevated blood
glucose levels by increased hepatic glucose efflux. Since obese
condition results in increased adipose tissue lipolysis leading to
increased plasma FFA, lipotoxicity that accumulation of bioactive
lipid intermediates inhibits insulin response has gained credibil-
ity for development of insulin resistance. Another possibility is
that the obesity activates adipose-derived cytokine production and
systemic inflammation and these cytokines disrupt signaling path-
ways in target tissues. Thus, adipose tissue is a primary location
for initiation of insulin resistance and subsequent development of
type 2 diabetes.
Free fatty acids are going through oxidative pathway to sup-
ply the energy for cell metabolism. Another route for FFAs is
sphingolipid biosynthetic pathway. Since FFAs are the substrate
and major constituents for sphingolipids, ceramide is elevated
in the patients with obesity or diabetes and has a positive cor-
relation with severity of insulin resistance (Haus et al., 2009).
Accumulating evidences suggest that sphingolipid metabolism is
a converging point linking excess FFAs and inflammation aroused
by adipose-derived inflammation, and contributes to progression
of insulin resistance. Ceramide and sphingosine inhibit insulin
actions and signaling by dephosphorylation and inhibition of
AKT and AMPK activity in various cell culture systems (Haj-
duch et al., 2001; Liu et al., 2004; Summers, 2006). Holland et al.
(2007) demonstrated that in vivo administration of myriocin, a
specific SPT inhibitor, improved glucocorticoid, saturated fat, and
obesity-induced insulin resistance by inhibiting de novo ceramide
synthesis. Heterozygous deficiency of dihydroceramide desaturase
(DES1) had improved insulin sensitivity and dexamethasone-
induced insulin resistance was prevented (Holland et al., 2007). In
cultured cells, the mechanisms of ceramide-mediated inhibition
of insulin response have been suggested. It has been demon-
strated that ceramide antagonized phosphorylation and activation
of AKT and tyrosine phosphorylation of insulin receptor substrate
(IRS-1) in 3T3-L1 adipocytes and C2C12 myocytes (Summers
et al., 1998; Chavez et al., 2003). Ceramide exerts its inhibitory
effects by activating protein phosphatase 2A (PP2A) responsible
for dephosphorylation of AKT (Dobrowsky et al., 1993). Addi-
tionally, ceramide activates PKCζ and inhibits translocation of
AKT to the membrane (Powell et al., 2003, 2004). By modulat-
ing AKT activity, ceramide inhibits insulin signaling pathway and
ultimately the insulin response is altered.
Since the finding that TNFα is linked to insulin resistance,
mechanism of obesity-induced inflammation has been suggested.
The activity of c-Jun N terminal kinase (JNK) is increased in the
obese mice and the lack of JNK showed improved glucose metab-
olism (Yuan et al., 2001). To support this finding, inhibition of
IKKβ by salicylate was effective in ameliorating inflammation-
mediated insulin resistance (Yuan et al.,2001). Since JNK and IKKβ
are activated by ceramide, occurrence of decreased insulin resis-
tance can be attributed to tissue ceramide levels (Ruvolo, 2003).
Especially, the reports that the absence of functional IKKβ by over-
expression of a kinase dead IKKβ decreases ceramide levels in
myocytes suggest that IKKβ regulates ceramide biosynthesis (Hol-
land et al., 2011a). Additionally, LPS-mediated NFκB activation
in macrophage upregulates transcription of enzymes involved in
de novo ceramide biosynthesis including Sptlc2 and acid SMase
(Chang et al., 2011). Thus, therapeutic intervention that lowers
inflammation together with in vivo ceramide production would
be a good target for obesity-mediated insulin resistance.
CERAMIDE AND HEPATIC STEATOSIS
Non-alcoholic fatty liver disease is a component of obesity-
mediated complications and defined as excess fat accumulation
in the liver (5–10% of liver weight) (Neuschwander-Tetri and
Caldwell, 2003). Initial development of NAFLD is the accumu-
lation of TAG in hepatocytes. Benign NAFLD, or hepatic steatosis,
at the beginning stage can develop into more malignant con-
ditions exemplified as steatohepatitis and cirrhosis (Farrell and
Larter, 2006; Kim and Younossi, 2008). Despite NAFLD is the
most common cause of hepatic dysfunction in the United States,
its pathogenesis is not completely understood.
Development of NAFLD is associated with overnutrition-
mediated obesity. Obesity-induced FFA increase in plasma con-
tributes to approximately 60% of accumulated TAG in the livers
of NAFLD patients (Donnelly et al., 2005). In obesity-induced
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insulin-resistant states, insulin is not able to inhibit the activity of
hormone-sensitive lipase in adipose tissues and release FFA into
circulation. Additionally, reduced glycerol-3-phosphate levels by
insulin resistance prevent reutilization of FFA for TAG synthesis
in adipocytes. Therefore, FFA spill from the adipose tissue to cir-
culation is a major cause of NAFLD prevalence. Accordingly, FFA
not utilized for TAG synthesis is shunted for ceramide synthesis
and ceramide levels are elevated in the adipose tissues from the
patients with NAFLD (Kolak et al., 2007). In obese ob/ob mice,
hepatic ceramide levels and the degree of steatosis demonstrated
a positive correlation (Yetukuri et al., 2007).
Clinically, association of inflammation with NAFLD was con-
firmed by the fact that patients with NAFLD have elevated lev-
els of TNFα (Jarrar et al., 2008) and expression of TNFα and
TNFα receptor are upregulated in the livers of the patients with
NAFLD compared to healthy individuals (Feldstein et al., 2004).
On the other hand, circulating adiponectin levels were reduced
in diet-induced obese (DIO) mice and hepatic expression of adi-
poR2, a predominant hepatic adiponectin receptor was downreg-
ulated (Peng et al., 2009). Additionally, the report that expression
of adiponectin is inversely correlated with expression of SMase
implies association of inflammation with sphingolipid biosyn-
thesis (Kolak et al., 2007). LPS treatment resulted in a two-fold
upregulation of hepatic Sptlc2 mRNA and activity and led to
increased hepatic SM and ceramide by twofold and threefold,
respectively (Memon et al., 1998). In this study, treatment of IL-1β
and TNFα upregulated Sptlc2 mRNA in hepatocytes and indicated
that fatty liver induces inflammation-mediated activation of de
novo biosynthesis.
Implication of SMase, a salvage pathway of ceramide, has been
suggested in NAFLD. SMase is regulated by inflammatory stim-
uli, including TNFα (Dressler et al., 1992; Schutze et al., 1992,
1995; Chatterjee, 1994). Binding of TNFα to p55 TNFα recep-
tor induced SMase transcription (Vandenabeele et al., 1995). Mice
deficient in acid SMase and LDL receptors were protected from
high fat diet-induced hepatic TAG accumulation (Deevska et al.,
2009). Moreover, hyperglycemia and insulin resistance were pre-
vented despite of elevated SM and other sphingolipids (Deevska
et al., 2009). In addition, pharmacological inhibition of SMase
in palmitic acid-treated hepatocytes reduced TAG significantly
(Deevska et al., 2009). These results suggest that SMase-mediated
ceramide production is implicated in hepatic steatosis in response
to elevated FA. The role of ceramide biosynthesis in development
of hepatic steatosis was demonstrated in DIO mice. SPT inhibition
by myriocin reduces hepatic TAG in DIO mice (Yang et al., 2009).
Reduced hepatic fat accumulation found in myriocin-treated DIO
mice implicates downregulation of SOCS-3, a gene involved in
development of hepatic steatosis (Ueki et al., 2004). Therefore,
regulation of SOCS-3 by ceramide biosynthesis contributes to the
pathophysiology of hepatic steatosis. However, whether ceramide
contributes to fatty liver directly or via secondary effects such as
increased FFA is not clear and need further studies.
SPHINGOLIPIDS AND ATHEROSCLEROSIS
Obesity-induced inflammation is implicated in increased risk
of coronary artery disease. Occurrence of cardiovascular
events involves a combined outcome of hyperlipidemia, insulin
resistance, hypertension, and heart failure. Recent literature sug-
gests that sphingolipids contribute to pathogenesis of CVD. The
fact that sphingolipid metabolism is regulated by inflammatory
state suggests that obesity-induced inflammation is the upstream
of sphingolipids and risk factors for etiology of various CVD
(Holland et al., 2011a). Among them, atherosclerosis is an inflam-
matory disease characterized by increased production of a wide
range of chemokines and cytokines. Early stage of atherogene-
sis involves the interaction of cholesterol-rich lipoproteins with
arterial wall (Ross, 1993). The processes implicated in early athero-
genesis include lipoprotein oxidation (Yla-Herttuala et al., 1989;
Witztum and Steinberg, 1991), lipoprotein retention and aggre-
gation (Nievelstein et al., 1991; Williams and Tabas, 1995, 1998;
Tabas et al., 2007), endothelial alteration, monocyte recruitment,
macrophage chemotaxis and foam cell formation, and smooth
muscle cell migration and alteration (Ross, 1993). An evidence
indicating the importance of SM in atherogenesis is that SM accu-
mulates in atherosclerotic plaques formed in human and animal
models (Smith, 1960; Newman et al., 1961; Phillips and Dodge,
1967; Portman and Illingworth, 1976; Hakomori, 1981; Kum-
merow et al., 2001). LDL extracted from human atherosclerotic
lesions has higher SM levels than LDL from plasma (Hoff and Mor-
ton, 1985; Guyton and Klemp, 1996; Schissel et al., 1996, 1998).
A substantial amount of the SM found in arteries and athero-
sclerotic lesions appears to arise from SM synthesis in the arterial
tissues (Zilversmit et al., 1961; Eisenberg et al., 1969). Plasma SM
levels in atherogenic apoE KO mice are fourfold higher than in
wild type mice (Jeong et al., 1998) and this may contribute to the
increased atherosclerosis (Plump et al., 1992; Zhang et al., 1992).
Clinically, Jiang et al. also found that human plasma SM levels and
SM/phosphatidylcholine (PC) ratio are independent risk factors
for occurrence of coronary heart disease (Jiang et al., 2000; Schlitt
et al., 2006).
Park et al. (2004) and Hojjati et al. (2005) have reported that
myriocin treatment reduces plasma SM levels and atherosclerosis
in apoE KO mice fed normal chow or HFD. While intraperitoneal
administration do not alter plasma lipids, myriocin treatment by
diet-admix also lower plasma lipid levels in apoE KO mice (Park
et al., 2004, 2008b). However, both diet-admix and intraperitoneal
administration methods led to reduced atherosclerosis, whereas
only oral administration of myriocin lowered plasma cholesterol
levels (Park et al., 2004; Hojjati et al., 2005). Oral administration
may reduce cholesterol absorption in small intestine (Li et al.,
2009). When wild type and apoE KO animals were treated with
myriocin, the mice absorbed significantly less cholesterol than
controls with no observable pathological changes in the small
intestine. Thus, myriocin has direct anti-atherosclerosis vascular
effects and also has the potential to function as a plasma lipid-
lowering agent. Similar to this study, administration of FTY720, an
analog of myriocin, also prevents atherosclerosis in apoE-deficient
mice (Liu et al., 2009).
In order to evaluate the role of SM in macrophage, Liu et al.
(2009) studied SMS2, SM synthase catalyzing formation of SM
from ceramide. In this report, SMS2 KO mouse bone marrow
was transplanted into LDL receptor KO (Ldlr−/−) mice. After
3 months on a Western diet, SMS2 deficiency decreased ather-
osclerotic lesions in the aortic arch, valve, and the entire aorta,
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compared with wild type macrophages transplanted into Ldlr−/−
mice. Moreover, the analysis of plaque morphology demonstrated
that SMS2 macrophage deficiency resulted in less necrotic core area
and more collagen content in atherosclerotic lesions (Liu et al.,
2009). Therefore, SMS2 deficiency in the macrophages reduces
atherosclerosis in mice.
CERAMIDE AND CARDIOMYOPATHY
Cardiomyopathy is an outcome of various chronic CVDs that is
often found in patients with diabetes. Weakening of the heart
is sometimes associated with increased heart content of lipids.
Diabetic cardiomyopathy contributes to increased morbidity
and mortality after myocardial infarction in diabetic patients
compared with non-diabetics (Stone et al., 1989). Inflammation is
closely associated with development of cardiac events derived from
diabetes. Kawamura et al. (2005) inactivates cardiac NFκB by over-
expressing a dominant negative NFκB subunit in cardiac-specific
TNFα transgenic mice. Although inactivation of NFκB blockage
did not improve myocardial inflammation which is represented
by inflammatory cell infiltration, it ameliorates cardiac function
and mortality. These findings suggest that activation of NFκB is
more important than inflammation-mediated immune reaction
in cardiomyopathy. To support this observation, TLR4 deficiency
attenuates cardiomyopathy in mice (Riad et al., 2008). These
FIGURE 3 | Elevated ceramide and SM in obese adipocytes elicit the pathophysiological events in various tissues and organs. CVD, cardiovascular
disease.
Table 1 | Alteration of tissue ceramide levels and related diseases in animal models of obesity and metabolic syndrome.
Animal models Reference Tissue Cer/SM changes Disease related
TLR4 KO mice Holland et al. (2011a) Skeletal muscle, liver Cer↓ Insulin sensitivity
AdipoR1, AdipoR2 (adenoviral
infection into C57BL/6J mice)
Holland et al. (2011b) Liver Cer↓ Insulin sensitivity
CPT-1c KO mice Gao et al. (2011) Hypothalamus Cer↓ Anorexia
Adipoq KO mice Holland et al. (2011b) Heart Cer↑ Insulin sensitivity
Des1± mice Holland et al. (2007) Heart, pancreas, WAT,
liver, soleus muscle
Cer↓ Improved insulin sensitivity
Syrian hamsters+LPS Memon et al. (1998) Liver Cer↑ Inflammation
Acidic SMase+LDLr−/− mice Deevska et al. (2009) Liver Cer↑ Steatosis
ApoE KO mice Jeong et al. (1998) Plasma SM↑ Atherosclerosis
SMS2−/−, LDLr−/− mice Liu et al. (2009) Macrophage Cer↑ SM↓ Reduced atherosclerosis
DIO mice Yang et al. (2009) Plasma, adipose Cer↑ Hepatic steatosis, insulin
resistance
LpLGPI mice Park et al. (2008a) Heart Cer↑ Cardiomyopathy
hSptlc2 KO mice Lee et al. (2012) Heart Cer↓ Cardiomyopathy
ob/ob mice Samad et al. (2006) Plasma Cer↑, SM↑ Obesity, diabetes, atherosclerosis
Adipose Cer↓, SM↓
Cer, ceramide; SM, sphingomyelin.
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findings support that an outcome of inflammation is involved
in the etiology of inflammation-induced cardiomyopathy.
Toll-like receptor 4 and NFκB, the mediators of inflammatory
response, regulate de novo sphingolipid biosynthesis (Chang et al.,
2011; Holland et al., 2011a; Schilling et al., 2013). Consistent with
these findings, Park et al. (2008a) reported the role of ceramide in
a lipotoxic cardiomyopathic mice model. Mice with cardiac over-
expression of glycosylphosphatidylinositol membrane-anchored
LpL mice (LpLGPI) also have increased cardiac ceramide and heart
failure markers (Yokoyama et al., 2004). Inhibition of de novo
ceramide biosynthesis by myriocin or heterozygous deletion of
Sptlc1 resulted in decreased expression of some apoptotic mark-
ers and ameliorated cardiac contraction in LpLGPI (Park et al.,
2008a). In this study, blockage of ceramide biosynthesis appears
to modulate mitochondrial substrate oxidation of FA and glucose.
A potential mechanism is that decreased ceramide by pharmaco-
logical and genetic inhibition of SPT upregulated pyruvate dehy-
drogenase kinase-4 and decreased the rate of glucose oxidation.
However,Lee et al. (2012) reported that ablation of cardiac-specific
Sptlc2 (hSptlc2 KO),an essential subunit of SPT, aggravates cardiac
function even with reduced ceramide and developed cardiomy-
opathy. A possible explanation about these inconsistent results is
that accumulated FA in hSptlc2 KO hearts due to inhibition of
de novo ceramide activates ER stress and increases cardiomyocytes
apoptosis. Therefore, a single lipid is unlikely to be reduced by inhi-
bition solely and cardiac lipotoxicity is caused by many processes
in proper heart function.
CERAMIDE AND VASCULAR DYSFUNCTION
Vascular dysfunction derived from obesity may be mediated by
lipotoxic metabolites. A growing body of literature suggests that
nitric oxide (NO) is a major modulator to maintain vascular func-
tion (Steinberg et al., 2000; Du et al., 2006; Symons et al., 2009).
As a ubiquitous signaling molecule, endothelial NO is responsible
for regulation of vasodilation (Alderton et al., 2001). Imbalance
between production and degradation of NO may lead to occur-
rence of cardiac events. Obesity mediates increased plasma FFA
and increased ceramide contents in various tissues contributing to
cardiovascular complications. Especially, ceramide inhibits signal-
ing kinases that phosphorylate endothelial NO synthase (eNOS)
at positive regulation site and activates signaling kinases that phos-
phorylate eNOS at negative regulatory sites (Wu et al., 2007;
Chavez and Summers, 2010; Summers, 2010). Recently, Zhang
et al. (2012) reported that inhibition of de novo ceramide biosyn-
thesis by myriocin ameliorates the blood pressure accrual in mice
fed a high fat diet. In this study, prevention of the blood pressure
increase by myriocin is endothelium-dependent and via restora-
tion of eNOS phosphorylation at Ser1177 (Zhang et al., 2012).
Moreover, heterozygous deficiency of dihydroceramide desaturase
(des±) partially restored phosphorylation of eNOS, suggesting a
major role of ceramide in NO production. A potential mecha-
nism responsible for aggravation of endothelial dysfunction by
ceramide is via ceramide-mediated activation of protein phos-
phatase 2A (PP2A) causing dephosphorylation of eNOS and AKT
dissociation. These findings provide the mechanistic link between
obesity-induced vascular dysfunction and ceramide.
SUMMARY
Obesity manifests in developed countries and contributes to the
prevalence of insulin resistance and cardiovascular risk. As a result,
obesity-induced inflammation had placed the adipose tissue at
the center of inflammation-related pathophysiology. When stor-
age capacity of adipose tissue exceeds its limit for fat deposition,
spillage of FFA and adipokines alters inflammatory states in vari-
ous tissues causing etiology of type 2 diabetes and vascular disease
(Figure 3). Due to diverse risk factors for inflammatory disease, it
is extremely important to find new approaches for better under-
standing of the disease. Recent findings suggest that sphingolipids
are critical mediators of obesity-mediated inflammation and CVD.
SM is implicated as a biochemical modulator of atherosclerosis and
ceramide acts as a metabolic switch regulating substrate preference
for cardiac energetics and NAFLD (Table 1). Although inflamma-
tion and sphingolipid metabolism are closely associated, a number
of clinical and experimental issues needs further clarification in
future. Moreover, new obesity- and sphingolipid-mediated disease
may be found. Thus, modulation of sphingolipid biosynthesis in
pathophysiological conditions explained in this review will pro-
vide a rationale for therapeutic intervention and present new
targets for inflammation-induced chronic diseases.
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